Patients randomized (n = 170; intent-to-treat population)

- Axitinib (continuous) + Pemetrexed/cisplatin (n = 55)
- Axitinib (modified) + Pemetrexed/cisplatin (n = 58)
- Pemetrexed/cisplatin alone (n = 57)
  - No treatment (n = 2)

Received treatment (n = 55; safety population)

Discontinued study (n = 55)
- Deaths (n = 37)
- Termination by sponsor (n = 13)
- Protocol violation (n = 2)
- Lost to follow-up (n = 1)
- Subject withdrawal (n = 1)
- Other (n = 1)

Discontinued study (n = 58)
- Deaths (n = 48)
- Termination by sponsor (n = 7)
- Protocol violation (n = 0)
- Lost to follow-up (n = 1)
- Subject withdrawal (n = 1)
- Other (n = 2)

Discontinued study (n = 55)
- Deaths (n = 31)
- Termination by sponsor (n = 14)
- Protocol violation (n = 1)
- Lost to follow-up (n = 1)
- Subject withdrawal (n = 1)
- Other (n = 4)